Ligand id: 8275

Name: niraparib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 72.94
Molecular weight 320.16
XLogP 2.71
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
The FDA granted niraparib orphan drug designation for the treatment of ovarian cancer [6]. This was converted to full approval in March 2017, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in a complete or partial response to platinum-based chemotherapy. This drug is administered orally, once-daily.
Phase III clinical trial in HER2 -ve/BRCA mutation +ve breast cancer (NCT01905592) is ongoing.
Mechanism Of Action and Pharmacodynamic Effects
PARP inhibitors may funtion by trapping PARPs on DNA [5], generating cytotoxic PARP-DNA complexes. PARP inhibition is particularly toxic in cancer cell lines [1-2]and human tumours [3] that lack the DNA repair mechanism of BRCA1 or BRCA2 ..